Sign in to comment!

Menu
Home

Mind and Body

New glaucoma treatment approved

0_21_450_Eye.jpg

Swiss pharmaceutical group Novartis said the European Commission has approved its eyecare unit Alcon's Simbrinza treatment for glaucoma, a chronic, sight-threatening eye disease.

Alcon said in a statement on Monday the Simbrinza eye drops suspension had been approved to decrease elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.

"We are pleased to introduce the only fixed combination therapy without a beta-blocker to help more glaucoma patients manage their progressive eye condition," Jeff George, global head of Alcon, said in the statement.